Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OZOBAX DS vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Treatment of spasticity associated with multiple sclerosis,Treatment of spinal cord injury-induced spasticity
Relief of discomfort associated with acute painful musculoskeletal conditions
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Hepatic metabolism via deamination; minor CYP450 involvement.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
20-30% bound to serum albumin.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: 95-100% (well absorbed); intravenous: 100%.
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
e GFR 30–59 m L/min/1.73 m²: 300 mg twice daily. e GFR 15–29 m L/min/1.73 m²: 200 mg twice daily. e GFR <15 m L/min/1.73 m²: 200 mg once daily.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 400 mg per day in divided doses. Child-Pugh Class C: not recommended.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Children (6–12 years): 10–15 mg/kg per dose twice daily, max 600 mg daily. Adolescents (12–18 years): same as adult dosing.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Start at the lower end of the dosing range (600 mg/day in divided doses) and titrate based on renal function; monitor for side effects.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
Abrupt discontinuation may precipitate withdrawal syndrome, including severe hyperthermia, altered mental status, and muscle rigidity, which can be life-threatening. Taper slowly.
None.
Risk of withdrawal syndrome with abrupt cessation,Dose-dependent sedation and dizziness may impair ability to drive or operate machinery,May exacerbate psychiatric disorders; use with caution in patients with depression or schizophrenia,Renal impairment requires dose adjustment,Respiratory depression risk, especially with concomitant CNS depressants
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to baclofen or any component of the formulation,Concurrent use of tricyclic antidepressants may increase risk of respiratory depression
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No specific food interactions; however, taking with food may reduce gastrointestinal discomfort.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to increase the incidence of omphalocele (ventral hernia) in fetuses of rats given approximately 3 times the maximum human dose. In rabbits, an increased incidence of incomplete ossification of sternal centers was observed. Cases of neonatal withdrawal syndrome have been reported with chronic maternal use during the third trimester, presenting as hypertonia, tremor, and seizures. Therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid use in the first trimester unless clearly needed.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Baclofen is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.4. The estimated infant dose from breast milk is about 0.1 mg/kg/day, which is less than 1% of the maternal weight-adjusted dose. No adverse effects in nursing infants have been reported. However, caution is advised, especially in premature infants or those with renal impairment. Monitor the infant for sedation, hypotonia, or feeding difficulties.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
During pregnancy, increased plasma volume and enhanced renal clearance may reduce baclofen plasma concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are limited. Dosing should be individualized based on clinical response. Monitor for deterioration of symptoms (e.g., increased spasticity) and adjust dose accordingly. If dose increased during pregnancy, reduce gradually postpartum to avoid withdrawal in both mother and neonate.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
OZOBAX DS (baclofen) is a GABA-B receptor agonist used for spasticity. Dosage titration is critical to avoid adverse effects. Abrupt discontinuation can cause withdrawal (hallucinations, seizures). Monitor for respiratory depression, especially in elderly or renal impairment. Consider dose adjustment in renal impairment (Cr Cl <30 m L/min).
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Take exactly as prescribed; do not stop suddenly.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol as it may worsen side effects.,Report any signs of withdrawal: confusion, hallucinations, seizures.,Take with food to reduce stomach upset.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OZOBAX DS vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
OZOBAX DS is a Skeletal Muscle Relaxant that works by Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OZOBAX DS and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OZOBAX DS is: Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OZOBAX DS and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OZOBAX DS is classified as Category C. Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to i. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.